ALNY News and Press, Alnylam Pharmaceuticals Inc. From 04/05/22

H.C. Wainwright urges investors to buy Alnylam Pharma (NASDAQ:ALNY) on the dip after the shares of the commercial-stage biotech dropped on Monday in reaction to a delay in the U.S. regulatory review for vutrisiran, an experimental therapy for transthyretin-mediated amyloidosis (ATTR-PN). The ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Blueprint Medicines (NASDAQ: BPMC ): initial data from a Phase 1/2 study of a lung cancer drug candidate for patients with certain types of mutation Bristol-Myers Squibb (NYSE: BMY ):  Food and Drug Admi...

RNAi therapeutics company, Alnylam Pharmaceuticals (NASDAQ:ALNY), announced on Monday that the U.S. Food and Drug Administration (FDA) extended its review period for vutrisiran, an experimental therapy for transthyretin-mediated (ATTR) amyloidosis. The FDA has made the decision to prolong the...

– New PDUFA goal date scheduled for July 14, 2022, due to amendment to address pending inspection classification at third-party secondary packaging and labeling facility – – New facility has been identified and incorporated into existing regulatory submiss...

Alnylam Pharmaceuticals (ALNY) rose 4%, paring some earlier gains on speculation that it cancelled from an investor event with Guggenheim. Alnylam (NASDAQ:ALNY) had been scheduled to meet with some clients at a rare disease/genomic event, according to speculations from traders ...

HQH has a strong and steady dividend history, supported by its earnings. HQH’s stock has performed poorly over the past 5 years, but over the long run it has generated stable price growth. Current price multiples and NAV indicates HQH is trading at a discount. For fur...

About a third of biotech companies will have one year of cash or less by the end of 2022, the Morgan Stanley analysts led by Matthew Harrison said this week based on a sample of 380 firms. While the number of companies requiring cash is similar to the levels seen before 2018 – 21, the ...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

GNOM lacks efficient portfolio reshuffling and may not be able to gain from higher alpha-producing stocks in the near future. Despite being a ‘Genomic Revolution’ fund, it lacks focus, and invested heavily on large cap diverse biotechnology companies. Better ‘...

Alnylam is an RNA-interference drug developer that was founded in 2002 and joined the Nasdaq in 2004. Alnylam Pharma has been studying Lipid Nanoparticle technology intensively for more than a decade and alleges it once shared its technology with Moderna in 2014. Alnylam is allegi...